TY - JOUR
T1 - Neuropsychiatric signs and symptoms of Alzheimer's disease
T2 - New treatment paradigms
AU - Lanctôt, Krista L.
AU - Amatniek, Joan
AU - Ancoli-Israel, Sonia
AU - Arnold, Steven E.
AU - Ballard, Clive
AU - Cohen-Mansfield, Jiska
AU - Ismail, Zahinoor
AU - Lyketsos, Constantine
AU - Miller, David S.
AU - Musiek, Erik
AU - Osorio, Ricardo S.
AU - Rosenberg, Paul B.
AU - Satlin, Andrew
AU - Steffens, David
AU - Tariot, Pierre
AU - Bain, Lisa J.
AU - Carrillo, Maria C.
AU - Hendrix, James A.
AU - Jurgens, Heidi
AU - Boot, Brendon
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/9
Y1 - 2017/9
N2 - Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.
AB - Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.
KW - Agitation
KW - Alzheimer's disease
KW - Apathy
KW - Delusions
KW - Depression
KW - Hallucinations
KW - Neuropsychiatric symptoms
KW - Sleep disturbance
KW - Trial design
UR - http://www.scopus.com/inward/record.url?scp=85027417429&partnerID=8YFLogxK
U2 - 10.1016/j.trci.2017.07.001
DO - 10.1016/j.trci.2017.07.001
M3 - Review article
C2 - 29067350
AN - SCOPUS:85027417429
SN - 2352-8737
VL - 3
SP - 440
EP - 449
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
IS - 3
ER -